MayaChen
Maya Chen is Pipeline Briefing's biotechnology correspondent, covering drug development and the investors financing it. She has a degree in molecular biology from UC San Diego.
Articles by Maya Chen
Investigations/September 12
What is Elevidys and how does it work?
Drug Pipeline/September 9
What are GLP-1 drugs and why are they so important?
Companies/August 23
Why is Novo Nordisk considered controversial in the United States?
Companies/August 13
Why is Sarepta so controversial?
Investigations/July 21
How was Elevidys first approved?
Drug Pipeline/July 19
How do US GLP-1 prices compare internationally?
Companies/July 1
What did the Senate find about Novo Nordisk and insulin prices?
Companies/June 21
What happened with the approval of Exondys 51 in 2016?
Investigations/May 30
Did Elevidys pass its confirmatory trial?
Drug Pipeline/May 27